{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:16:39Z","timestamp":1793276199657,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003512","name":"State Administration of Foreign Experts Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003512","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003398","name":"Shanxi scholarship council of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003398","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","neuropeptidesjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropeptides"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.npep.2018.07.003","type":"journal-article","created":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T13:03:11Z","timestamp":1531314191000},"page":"70-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":138,"special_numbering":"C","title":["Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model"],"prefix":"10.1016","volume":"71","author":[{"given":"Liping","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"H\u00f6lscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.npep.2018.07.003_bb0005","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/nrn1434","article-title":"Oxidative stress in neurodegeneration: cause or consequence?","volume":"10","author":"Andersen","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.npep.2018.07.003_bb0010","first-page":"25","article-title":"Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease","volume":"12","author":"Anglade","year":"1997","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.npep.2018.07.003_bb0015","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"6736","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.npep.2018.07.003_bb0020","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson's disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.npep.2018.07.003_bb0025","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3233\/JPD-140364","article-title":"Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease","volume":"4","author":"Aviles-Olmos","year":"2014","journal-title":"J. Parkinson's Dis."},{"key":"10.1016\/j.npep.2018.07.003_bb0030","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.npep.2018.07.003_bb0035","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0092-8674(00)80086-0","article-title":"Atm-deficient mice: a paradigm of ataxia telangiectasia","volume":"86","author":"Barlow","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.npep.2018.07.003_bb0040","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.4161\/cc.28295","article-title":"Involvement of peroxisome proliferator-activated receptor beta\/delta (PPAR beta\/delta) in BDNF signaling during aging and in Alzheimer disease: possible role of 4-hydroxynonenal (4-HNE)","volume":"13","author":"Benedetti","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.npep.2018.07.003_bb0045","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jnr.21483","article-title":"Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease","volume":"86","author":"Bertilsson","year":"2010","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.npep.2018.07.003_bb0050","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1083\/jcb.200507002","article-title":"p62\/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death","volume":"171","author":"Bj\u00f8rk\u00f8y","year":"2005","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.npep.2018.07.003_bb0055","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neuroscience.2011.10.057","article-title":"Neurotoxin-based models of Parkinson's disease","volume":"211","author":"Bov\u00e9","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.npep.2018.07.003_bb0060","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.npep.2018.07.003_bb0065","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.2337\/dc11-1584","article-title":"Diabetes and risk of Parkinson's disease: a systematic review and meta-analysis","volume":"34","author":"Cereda","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.npep.2018.07.003_bb0070","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev-physiol-021113-170315","article-title":"Glucagon-like peptide-1: glucose homeostasis and beyond","volume":"76","author":"Cho","year":"2014","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.npep.2018.07.003_bb0075","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.nbd.2009.05.023","article-title":"Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions","volume":"35","author":"Chu","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.npep.2018.07.003_bb0080","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1742-2094-11-51","article-title":"Inflammation-sleep interface in brain disease: TNF, insulin, orexin","volume":"11","author":"Clark","year":"2014","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.npep.2018.07.003_bb0085","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/brain\/122.8.1437","article-title":"The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease","volume":"122","author":"Damier","year":"1999","journal-title":"Brain"},{"key":"10.1016\/j.npep.2018.07.003_bb0090","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-018-0871-0","article-title":"Semaglutide: First Global Approval","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.npep.2018.07.003_bb0095","doi-asserted-by":"crossref","first-page":"27879","DOI":"10.1074\/jbc.M110.119537","article-title":"Nix is critical to two distinct phases of mitophagy, reactive oxygen species-mediated autophagy induction and Parkin-ubiquitin-p62-mediated mitochondrial priming","volume":"285","author":"Ding","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.npep.2018.07.003_bb0100","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1124\/pr.55.1.7","article-title":"Pharmacological agents that directly modulate insulin secretion","volume":"55","author":"Doyle","year":"2003","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.npep.2018.07.003_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1385\/ENDO:27:1:001","article-title":"In vivo biological activity of exendin (1\u221230)","volume":"27","author":"Doyle","year":"2005","journal-title":"Endocrine"},{"issue":"2011","key":"10.1016\/j.npep.2018.07.003_bb0110","first-page":"436813","article-title":"Parkinson's disease and systemic inflammation","volume":"2011","author":"Ferrari","year":"2011","journal-title":"Parkinson's Dis."},{"key":"10.1016\/j.npep.2018.07.003_bb0115","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40263-013-0076-8","article-title":"Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence","volume":"27","author":"Freiherr","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.npep.2018.07.003_bb0120","doi-asserted-by":"crossref","first-page":"842","DOI":"10.2337\/dc06-2011","article-title":"Type 2 diabetes and the risk of Parkinson's disease","volume":"30","author":"Gang","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.npep.2018.07.003_bb0125","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0922-4106(91)90073-Q","article-title":"MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease","volume":"208","author":"Gerlach","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.npep.2018.07.003_bb0130","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s12035-013-8404-z","article-title":"Brain insulin dysregulation: implication for neurological and neuropsychiatric disorders","volume":"47","author":"Ghasemi","year":"2013","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.npep.2018.07.003_bb0135","first-page":"65","article-title":"The role of MAO in MPTP toxicity\u2014a review","volume":"20","author":"Glover","year":"1986","journal-title":"J. Neural Transm. Suppl."},{"key":"10.1016\/j.npep.2018.07.003_bb0140","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF02741387","article-title":"Tyrosine hydroxylase and Parkinson's disease","volume":"16","author":"Haavik","year":"1998","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.npep.2018.07.003_bb0145","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/j.1471-4159.2006.03907.x","article-title":"Oxidative stress and neurodegeneration: where are we now?","volume":"97","author":"Halliwell","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.npep.2018.07.003_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-2094-5-19","article-title":"Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease","volume":"5","author":"Harkavyi","year":"2008","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.npep.2018.07.003_bb0155","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.bbrc.2016.05.086","article-title":"GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK\/mTOR pathway","volume":"476","author":"He","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.npep.2018.07.003_bb0160","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/14712598.2018.1439014","article-title":"Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes","volume":"18","author":"Hedrington","year":"2018","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.npep.2018.07.003_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2018.01.040","article-title":"Novel dual GLP-1\/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models","author":"H\u00f6lscher","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.npep.2018.07.003_bb0170","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1517\/14728214.9.1.155","article-title":"Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors","volume":"9","author":"Holst","year":"2004","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.npep.2018.07.003_bb0175","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3233\/JPD-140364","article-title":"Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease","volume":"4","author":"Iciar","year":"2014","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.npep.2018.07.003_bb0180","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/jnc.13736","article-title":"Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells","volume":"139","author":"Jalewa","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.npep.2018.07.003_bb0185","first-page":"184","article-title":"Liraglutide improves the survival of INS-1 cells by promoting macroautophagy","volume":"11","author":"Jia","year":"2013","journal-title":"Int. J. Endocrinol. Metabol."},{"key":"10.1016\/j.npep.2018.07.003_bb0190","doi-asserted-by":"crossref","first-page":"279","DOI":"10.4161\/auto.7.3.14487","article-title":"Selective autophagy mediated by autophagic adapter proteins","volume":"7","author":"Johansen","year":"2011","journal-title":"Autophagy"},{"key":"10.1016\/j.npep.2018.07.003_bb0195","article-title":"GIP stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3-K)\/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1 and downregulation of bax expression","volume":"41","author":"Kim","year":"2005","journal-title":"Phys. Rev. B"},{"key":"10.1016\/j.npep.2018.07.003_bb0200","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1677\/JOE-09-0132","article-title":"Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease","volume":"202","author":"Kim","year":"2009","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.npep.2018.07.003_bb0205","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1523\/JNEUROSCI.4261-15.2016","article-title":"Pathogenic upregulation of glial lipocalin-2 in the parkinsonian dopaminergic system","volume":"36","author":"Kim","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.npep.2018.07.003_bb0210","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0197-0186(87)90024-6","article-title":"The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (mptp) and its relevance to parkinson's disease","volume":"11","author":"Kinemuchi","year":"1987","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.npep.2018.07.003_bb0215","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.molcel.2009.04.026","article-title":"A role for ubiquitin in selective autophagy","volume":"34","author":"Kirkin","year":"2009","journal-title":"Mol. Cell"},{"key":"10.1016\/j.npep.2018.07.003_bb0220","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev.ne.11.030188.000501","article-title":"MPTP toxicity: implications for research in Parkinson's disease","volume":"11","author":"Kopin A","year":"1988","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.npep.2018.07.003_bb0225","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/mds.25292","article-title":"The current and projected economic burden of Parkinson's disease in the United States","volume":"28","author":"Kowal","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.npep.2018.07.003_bb0230","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0806720106","article-title":"GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism","volume":"106","author":"Li","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.npep.2018.07.003_bb0235","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejphar.2016.11.050","article-title":"D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation","volume":"797","author":"Li","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.npep.2018.07.003_bb0240","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ejphar.2015.08.038","article-title":"Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease","volume":"765","author":"Liu","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.npep.2018.07.003_bb0245","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","article-title":"Neuroprotective effects of lixisenatide and liraglutide in the MPTP mouse model of Parkinson's disease","volume":"303","author":"Liu","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.npep.2018.07.003_bb0250","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jcjd.2017.08.242","article-title":"Glucagon-like peptide-1 receptor agonists: a class update for treating type 2 diabetes","volume":"41","author":"Lovshin","year":"2017","journal-title":"Can. J. Diabetes"},{"key":"10.1016\/j.npep.2018.07.003_bb0255","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.pneurobio.2006.06.003","article-title":"Insulin signaling in the central nervous system: learning to survive","volume":"79","author":"Lp","year":"2006","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.npep.2018.07.003_bb0260","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.3390\/ijms15045596","article-title":"Transcriptional analysis of apoptotic cerebellar granule neurons following rescue by gastric inhibitory polypeptide","volume":"15","author":"Maino","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.npep.2018.07.003_bb0265","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1021\/jm500810s","article-title":"Glucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications","volume":"58","author":"Manandhar","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.npep.2018.07.003_bb0270","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2009.03.048","article-title":"Autophagy suppresses tumorigenesis through elimination of p62","volume":"137","author":"Mathew","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.npep.2018.07.003_bb0275","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2010.03.002","article-title":"Case-control study of risk of Parkinson's disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan","volume":"293","author":"Miyake","year":"2010","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.npep.2018.07.003_bb0280","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF00313602","article-title":"Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease","volume":"87","author":"Moroo","year":"1994","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.npep.2018.07.003_bb0285","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.expneurol.2011.06.005","article-title":"Insulin resistance impairs nigrostriatal dopamine function","volume":"231","author":"Morris","year":"2011","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.npep.2018.07.003_bb0290","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0304-3940(86)90282-X","article-title":"Histochemistry of MPTP oxidation in the rat brain: sites of synthesis of the parkinsonism-inducing toxin MPP +","volume":"65","author":"Nakamura","year":"1986","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.npep.2018.07.003_bb0295","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.npep.2018.07.003_bb0300","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-16488-x","article-title":"Liraglutide restores chronic ER stress, autophagy impairments and apoptotic signalling in SH-SY5Y cells","volume":"7","author":"Panagaki","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.npep.2018.07.003_bb0305","series-title":"Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"1997"},{"key":"10.1016\/j.npep.2018.07.003_bb0310","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2174\/138161211795164095","article-title":"The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease","volume":"17","author":"Prediger","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.npep.2018.07.003_bb0315","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00702-011-0758-7","article-title":"Reactive oxygen\/nitrogen species and their functional correlations in neurodegenerative diseases","volume":"119","author":"Ramalingam","year":"2012","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.npep.2018.07.003_bb0320","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/WCO.0b013e3283633741","article-title":"Recent developments in biomarkers in Parkinson disease","volume":"26","author":"Schapira","year":"2013","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.npep.2018.07.003_bb0325","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.2337\/dc10-1333","article-title":"Diabetes and the risk of developing Parkinson's disease in Denmark","volume":"34","author":"Schernhammer","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.npep.2018.07.003_bb0330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025269","article-title":"GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy","volume":"6","author":"Sharma","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.npep.2018.07.003_bb0335","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0006-8993(97)00429-0","article-title":"Mitochondrial toxins in models of neurodegenerative diseases. I: in vivo brain hydroxyl radical production during systemic MPTP treatment or following microdialysis infusion of methylpyridinium or azide ions","volume":"765","author":"Smith","year":"1997","journal-title":"Brain Res."},{"key":"10.1016\/j.npep.2018.07.003_bb0340","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.coph.2013.09.005","article-title":"Gut hormones as therapeutic agents in treatment of diabetes and obesity","volume":"13","author":"Tan","year":"2013","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.npep.2018.07.003_bb0345","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/hepr.12634","article-title":"Liraglutide ameliorates non-alcoholic fatty liver disease by enhancing mitochondrial architecture and promoting autophagy through the SIRT1\/SIRT3-FOXO3a pathway","volume":"46","author":"Tong","year":"2016","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.npep.2018.07.003_bb0350","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1358\/dot.2009.45.2.1336104","article-title":"Liraglutide: a new treatment for type 2 diabetes","volume":"45","author":"Vilsboll","year":"2009","journal-title":"Drugs Today"},{"key":"10.1016\/j.npep.2018.07.003_bb0355","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.parkreldis.2012.03.010","article-title":"Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort","volume":"18","author":"Wahlqvist","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.npep.2018.07.003_bb0360","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.3892\/mmr.2015.3944","article-title":"Liraglutide protects pancreatic \u03b2-cells against free fatty acidsin vitroand affects glucolipid metabolism in apolipoprotein E\u2212\/\u2212 mice by activating autophagy","volume":"12","author":"Wang","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.npep.2018.07.003_bb0365","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/dc11-1511","article-title":"Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications","volume":"35","author":"Yu","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.npep.2018.07.003_bb0370","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bbr.2015.07.021","article-title":"Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson's disease mouse model","volume":"293","author":"Zhang","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.npep.2018.07.003_bb0375","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.3892\/mmr.2014.2569","article-title":"Liraglutide reduces lipid accumulation in steatotic L-02 cells by enhancing autophagy","volume":"10","author":"Zhou","year":"2014","journal-title":"Mol. Med. Rep."}],"container-title":["Neuropeptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143417918300684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143417918300684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T11:33:01Z","timestamp":1604575981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0143417918300684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":75,"alternative-id":["S0143417918300684"],"URL":"https:\/\/doi.org\/10.1016\/j.npep.2018.07.003","relation":{},"ISSN":["0143-4179"],"issn-type":[{"value":"0143-4179","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model","name":"articletitle","label":"Article Title"},{"value":"Neuropeptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.npep.2018.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}